Botulinum toxin type A in aesthetic correction of the face: traditions, innovations and personal experience

Close metadata

OBJECTIVE

To assess effectiveness and safety, as well as the author’s experience of full face correction with Onabotulinumtoxin A.

MATERIAL AND METHODS

The author analyzed 183 patients who received a combination of BTA injections in the upper and lower or middle third of the face within a year. In addition to the upper face, injections into m. masseter, m. platysma, m. depressor anguli oris and m. mentalis were common. The minimum dose for full face correction was 50 units, maximum dose — 150 units.

RESULTS

Botulinum toxin therapy with OnabotulinumtoxinA was effectivene and safe for full face correction. This approach resulted high satisfaction in patients.

CONCLUSION

Full face technique provides more stable and harmonious results compared to isolated correction of the upper face. However, botulinum toxin therapy with full face correction may be recommended only for well-experienced specialists considering anatomical features.

Keywords:

correction of the upper third of the face

botulinum toxin type A

full face

botulinum therapy

OnabotulinumtoxinA

ptosis

Authors:

E.V. Kruglik

VIP-Clinic Moscow

Received:

15.06.2022

Accepted:

04.10.2022

List of references:

Fagien S. Botox for the treatment of dynamic and hyperkinetic facial lines and furrows: adjunctive use in facial aesthetic surgery. Plast Reconstr Surg. 1999;103(2):701-713.
Blitzer A, Binder WJ, Aviv JE, Keen MS, Brin MF. The management of hyperfunctional facial lines with botulinum toxin. A collaborative study of 210 injection sites in 162 patients. Arch Otolaryngol Head Neck Surg. 1997;123(4): 389-392.
Schlessinger J. Gilbert E, Cohen JL, Kaufman J. New Uses of AbobotulinumtoxinA in Aesthetics. Aesthet Surg J. 2017;37(Suppl 1):45-58.
Monheit GD, Pickett A. AbobotulinumtoxinA: A 25-Year History. Aesthet Surg J. 2017;37(Suppl 1):4-11.
Instruktsiya po meditsinskomu primeneniyu preparata Botoks. Registratsionnoe udostoverenie LP-002949 preparata Botoks, liofilizat dlya prigotovleniya rastvora dlya vnutrimyshechnogo vvedeniya, 100 ED. (In Russ.).
D’Emilio R, Rosati G. Full-face treatment with onabotulinumtoxinA: Results from a single-center study. J Cosmet Dermatol. 2020;19(4):809-816.
Kapuler OM, Razumovskaya EA. Use of botulinum toxin in facial aesthetic correction: 10 years of practice and new guidelines. Plastic Surgery and Aesthetic Medicine. 2021;3:60-67. (In Russ., In Engl.).
Polo M. Botulinum toxin type A (Botox) for the neuromuscular correction of excessive gingival display on smiling (gummy smile). Am J Orthod Dentofacial Orthop. 2008;133(2):195-203.
Zabnenkova OV. Intradermal fillers on the basis of the hyaluronic acid. Indications, possible combinations. Plasticheskaya khirurgiya i kosmetologiya. 2010;1:101-112. (In Russ.).
Sundaram H, Signorini M, Liew S, et al. Global Aesthetics Consensus: Botulinum Toxin Type A — Evidence-Based Review, Emerging Concepts, and Consensus Recommendations for Aesthetic Use, Including Updates on Complications. Plast Reconstr Surg. 2016;137(3):518-529.
Bertossi D, Cavallini M, Cirillo P, et al. Italian consensus report on the aesthetic use of onabotulinum toxin A. J Cosmet Dermatol. 2018;17(5):719-730.
Monheit G. Neurotoxins: Current Concepts in Cosmetic Use on the Face and Neck — Upper Face (Glabella, Forehead, and Crow’s Feet). Plast Reconstr Surg. 2015;136(5 Suppl):72-75.
Levy PM. Neurotoxins: Current Concepts in Cosmetic Use on the Face and Neck — Jawline Contouring/Platysma Bands/Necklace Lines. Plast Reconstr Surg. 2015;136(5 Suppl):80-83.
Wu DC, Fabi SG, Goldman MP. Neurotoxins: Current Concepts in Cosmetic Use on the Face and Neck — Lower Face. Plast Reconstr Surg. 2015; 136(5 suppl):76-79.
Raspaldo H, Niforos F-R, Gassia V, et al. Lower-face and neck antiaging treatment and prevention using onabotulinumtoxin A: The 2010 multidisciplinary French consensus — part 2. J Cosmet Dermatol. 2011;10(2):131-149.
Raspaldo H, Baspeyras M, Bellity P, et al. Upper- and mid-face anti-aging treatment and prevention using onabotulinumtoxin A: The 2010 multidisciplinary French consensus — part 1. J Cosmet Dermatol. 2011;10(1):36-50.
Carruthers J, Carruthers A. Aesthetic botulinum A toxin in the mid and lower face and neck. Dermatol Surg. 2003;29(5):468-476.
De Maio M, Wu WTL, Goodman GJ, Monheit G, Alliance for the Future of Aesthetics Consensus Committee. Facial Assessment and Injection Guide for Botulinum Toxin and Injectable Hyaluronic Acid Fillers: Focus on the Lower Face. Plast Reconstr Surg. 2017;140(3):393-404.
De Maio M, Swift A, Signorini M, Fagien S, Aesthetic Leaders in Facial Aesthetics Consensus Committee. Facial Assessment and Injection Guide for Botulinum Toxin and Injectable Hyaluronic Acid Fillers: Focus on the Upper Face. Plast Reconstr Surg. 2017;140(2):265-276.
De Maio M, DeBoulle K, Braz A, Rohrich RJ, Alliance for the Future of Aesthetics Consensus Committee. Facial Assessment and Injection Guide for Botulinum Toxin and Injectable Hyaluronic Acid Fillers: Focus on the Midface. Plast Reconstr Surg. 2017;140(4):540-550.
Kaminer MS, Cox SE, Fagien S, Kaufman J, Lupo MP, Shamban A. Re-examining the Optimal Use of Neuromodulators and the Changing Landscape: A Consensus Panel Update. J Drugs Dermatol. 2020;19(4):5-15. Erratum in: J Drugs Dermatol. 2020;19(5):S1545961620P0010X.
Thiesen G, Gribel BF, Freitas MP. Facial asymmetry: A current review. Dental Press J Orthod. 2015;20(6):110-125. PMID: 26691977; PMCID: PMC4686752. https://doi.org/10.1590/2177-6709.20.6.110-125.sar
Cheong YW, Lo LJ. Facial asymmetry: etiology, evaluation, and management. Chang Gung Med J. 2011;34(4):341-351. PMID: 21880188.
Sethi N, Singh S, DeBoulle K, Rahman E. A Review of Complications Due to the Use of Botulinum Toxin A for Cosmetic Indications. Aesthetic Plast Surg. 2021;45(3):1210-1220. Epub 2020 Oct 13. Erratum in: Aesthetic Plast Surg. 2022;46(1):595. PMID: 33051718. https://doi.org/10.1007/s00266-020-01983-w
King M. Management of Ptosis. J Clin Aesthet Dermatol. 2016;9(12):1-4. Epub 2016 Dec 01. PMID: 28210399; PMCID: PMC5300727.

Close metadata